Top

Published in:

Open Access 01-12-2024 | COVID-19 | Research

Trends in gynaecologic cancer mortality and the impact of the COVID-19 pandemic in the United States

Authors: Yuyan Xi, Yuxin Guo, Sikai Qiu, Fan Lv, Yujiao Deng, Jingyi Xie, Zixuan Xing, Yajing Bo, Chenyu Chang, Fan Zhang, Fanpu Ji, Mu Li

Published in: Infectious Agents and Cancer | Issue 1/2024

Abstract

Objectives

Our aim was to assess the trend in gynaecologic cancer (GC) mortality in the period from 2010 to 2022 in the United States, with focus on the impact of the pandemic on increased deaths.

Methods

GC mortality data were extracted from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform. We analysed mortality trends and evaluated observed vs. predicted mortality for the period from 2020 to 2022 with joinpoint regression and prediction modelling analyses.

Results

A total of 334,382 deaths among adults aged 25 years and older with gynaecologic cancer were documented from 2010 to 2022. The overall age-standardised mortality rate (ASMR, per 100,000 persons) for ovarian cancer-related death decreased gradually from 7.189 in 2010 to 5.517 in 2019, yielding an APC (annual percentage change) of -2.8%. However, the decrease in ovarian cancer-related mortality slowed down by more than 4-fold during the pandemic. Cervical cancer -related mortality decreased slightly prior to the pandemic and increased during the pandemic with an APC of 0.6%, resulting in excess mortality of 4.92%, 9.73% and 2.03% in 2020, 2021 and 2022, respectively. For uterine corpus cancer, the ASMR increased from 1.905 in 2010 to 2.787 in 2019, and increased sharply to 3.079 in 2021 and 3.211 in 2022. The ASMR rose steadily between 2013 and 2022, yielding an APC of 6.9%.

Conclusions

Overall, we found that GC-related mortality increased during the COVID-19 pandemic, and this increase was not specific to age, race, or ethnicity.

Available only for authorised users

Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C. Global trends and predictions in ovarian cancer mortality. Annals Oncology: Official J Eur Soc Med Oncol. 2016;27(11):2017–25. https://doi.org/10.1093/annonc/mdw306.CrossRef

Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA: a cancer journal for clinicians. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Tabibi T, Barnes JM, Shah A, Osazuwa-Peters N, Johnson KJ, Brown DS. Human papillomavirus vaccination and Trends in Cervical Cancer incidence and mortality in the US. JAMA Pediatr. 2022;176(3):313–6. https://doi.org/10.1001/jamapediatrics.2021.4807.CrossRefPubMed

Giaquinto AN, Broaddus RR, Jemal A, Siegel RL. The changing Landscape of Gynecologic Cancer Mortality in the United States. Obstet Gynecol. 2022;139(3):440–2. https://doi.org/10.1097/aog.0000000000004676.CrossRefPubMedPubMedCentral

Estimating excess mortality. Due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet (London England). 2022;399(10334):1513–36. https://doi.org/10.1016/s0140-6736(21)02796-3.CrossRef

Lv F, Gao X, Huang AH, Zu J, He X, Sun X, et al. Excess diabetes mellitus-related deaths during the COVID-19 pandemic in the United States. EClinicalMedicine. 2022;54:101671. https://doi.org/10.1016/j.eclinm.2022.101671.CrossRefPubMedPubMedCentral

Gao X, Lv F, He X, Zhao Y, Liu Y, Zu J, et al. Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States. J Hepatol. 2023;78(1):16–27. https://doi.org/10.1016/j.jhep.2022.07.028.CrossRefPubMed

Lara OD, O’Cearbhaill RE, Smith MJ, Sutter ME, Knisely A, McEachron J, et al. COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer. 2020;126(19):4294–303. https://doi.org/10.1002/cncr.33084.CrossRefPubMed

10.

Frey MK, Fowlkes RK, Badiner NM, Fishman D, Kanis M, Thomas C, et al. Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020;159(2):470–5. https://doi.org/10.1016/j.ygyno.2020.09.005.CrossRefPubMedPubMedCentral

11.

Henley SJ, Dowling NF, Ahmad FB, Ellington TD, Wu M, Richardson LC. COVID-19 and other underlying causes of cancer deaths - United States, January 2018-July 2022. MMWR Morb Mortal Wkly Rep. 2022;71(50):1583–8. https://doi.org/10.15585/mmwr.mm7150a3

12.

Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: a perspective. J Global Health. 2020;10(1):010367. https://doi.org/10.7189/jogh.10.010367.CrossRef

13.

Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, et al. Association of insurance with cancer care utilization and outcomes. Cancer J Clin. 2008;58(1):9–31. https://doi.org/10.3322/ca.2007.0011.CrossRef

14.

Jambunathan B, Lang J, Mays M, Ekwenna O. Quantifying mortality burden in patients with cancer due to COVID-19 in the US: a national cross-sectional analysis. Cancer Med. 2023;12(16):17413–7. https://doi.org/10.1002/cam4.6364.CrossRefPubMedPubMedCentral

15.

Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314–20. https://doi.org/10.1038/sj.bjc.6603457.CrossRefPubMedPubMedCentral

16.

Selle F, Colombo N, Korach J, Mendiola C, Cardona A, Ghazi Y, et al. Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥ 70 years) versus younger patients treated for newly diagnosed ovarian Cancer in the International ROSiA Study. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2018;28(4):729–37. https://doi.org/10.1097/igc.0000000000001221.CrossRef

17.

Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(29):3921–6. https://doi.org/10.1200/jco.2010.34.1552.CrossRef

18.

Yeo YH, He X, Lv F, Zhao Y, Liu Y, Yang JD, et al. Trends of Cirrhosis-related Mortality in the USA during the COVID-19 pandemic. J Clin Transl Hepatol. 2023 Jun;11(3):751–6. https://doi.org/10.14218/JCTH.2022.00313

19.

Mortality. Pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet (London England). 2020;396(10243):27–38. https://doi.org/10.1016/s0140-6736(20)31182-x.CrossRef

20.

Karia PS, Tehranifar P, Visvanathan K, Wright JD, Genkinger JM. Cancer-Specific Mortality in Asian American Women Diagnosed with Gynecologic Cancer: A Nationwide Population-Based Analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2022;31(3):578–87. https://doi.org/10.1158/1055-9965.Epi-21-0829.

21.

Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, et al. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018;151(2):269–74. https://doi.org/10.1016/j.ygyno.2018.08.041.CrossRefPubMedPubMedCentral

22.

McCoy RG, Campbell RL, Mullan AF, Bucks CM, Clements CM, Reichard RR, et al. Changes in all-cause and cause-specific mortality during the first year of the COVID-19 pandemic in Minnesota: population-based study. BMC Public Health. 2022;22(1):2291. https://doi.org/10.1186/s12889-022-14743-z.CrossRefPubMedPubMedCentral

23.

Zhao Y, Yeo YH, Samaan J, Lv F, He X, Liu J, et al. Racial and ethnic disparities in years of potential life loss among patients with cirrhosis during the COVID-19 pandemic in the United States. Am J Gastroenterol. 2023;118(4):752–7. https://doi.org/10.14309/ajg.0000000000002191.CrossRefPubMed

24.

Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103(6):1258–64. https://doi.org/10.1002/cncr.20877.CrossRefPubMed

25.

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (London England). 2014;383(9916):524–32. https://doi.org/10.1016/s0140-6736(13)62218-7.CrossRefPubMed

26.

Shahmoradi Z, Damgacioglu H, Clarke MA, Wentzensen N, Montealegre J, Sonawane K, et al. Cervical Cancer incidence among US women, 2001–2019. JAMA. 2022. https://doi.org/10.1001/jama.2022.17806.CrossRefPubMedPubMedCentral

27.

Min Y, Liu Z, Huang R, Li R, Jin J, Wei Z, et al. Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study. J Translational Med. 2022;20(1):560. https://doi.org/10.1186/s12967-022-03719-7.CrossRef

28.

Feldman S, Alimena S. Cervical Cancer Prevention and cost for women older Than 65 years in the US-Are we spending too much or too little? JAMA Intern Med. 2023;183(1):20–1. https://doi.org/10.1001/jamainternmed.2022.5251.CrossRefPubMed

29.

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in Endometrial Cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110(4):354–61. https://doi.org/10.1093/jnci/djx214.CrossRefPubMed

30.

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet (London England). 2011;377(9765):557–67. https://doi.org/10.1016/s0140-6736(10)62037-5.CrossRefPubMed

31.

Mullins MA, Cote ML. Beyond obesity: the rising incidence and mortality rates of Uterine Corpus Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(22):1851–3. https://doi.org/10.1200/jco.19.01240.CrossRef

32.

Finer LB, Philbin JM. Trends in ages at key reproductive transitions in the United States, 1951–2010. Women’s Health Issues: Official Publication Jacobs Inst Women’s Health. 2014;24(3):e271–9. https://doi.org/10.1016/j.whi.2014.02.002.

33.

Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-corrected uterine Corpus Cancer Incidence trends and Differences in Relative Survival Reveal Racial Disparities and rising rates of nonendometrioid cancers. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(22):1895–908. https://doi.org/10.1200/jco.19.00151.CrossRef

34.

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US Cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708–e. https://doi.org/10.1001/jamanetworkopen.2021.4708.CrossRefPubMedPubMedCentral

35.

Magliano DJ, Chen L, Carstensen B, Gregg EW, Pavkov ME, Salim A, et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes Endocrinol. 2022;10(2):112–9. https://doi.org/10.1016/s2213-8587(21)00327-2.CrossRefPubMed

36.

Yeo YH, Wang M, He X, Lv F, Zhang Y, Zu J, et al. Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic. J Med Virol. 2023;95(1):e28187. https://doi.org/10.1002/jmv.28187.CrossRefPubMed

37.

Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular deaths during the COVID-19 pandemic in the United States. J Am Coll Cardiol. 2021;77(2):159–69. https://doi.org/10.1016/j.jacc.2020.10.055.CrossRefPubMedPubMedCentral

38.

Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing Burden of Endometrial Cancer: a Major Racial Disparity Affecting Black Women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015;24(9):1407–15. https://doi.org/10.1158/1055-9965.Epi-15-0316.

39.

Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57. https://doi.org/10.1093/jnci/94.5.334.CrossRefPubMed

40.

Geronimus AT, Hicken M, Keene D, Bound J. Weathering and age patterns of allostatic load scores among blacks and whites in the United States. Am J Public Health. 2006;96(5):826–33. https://doi.org/10.2105/ajph.2004.060749.CrossRefPubMedPubMedCentral

41.

Siegel RL, Devesa SS, Cokkinides V, Ma J, Jemal A. State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(1):25–31. https://doi.org/10.1158/1055-9965.Epi-12-0991.

Title: Trends in gynaecologic cancer mortality and the impact of the COVID-19 pandemic in the United States
Authors: Yuyan Xi
Yuxin Guo
Sikai Qiu
Fan Lv
Yujiao Deng
Jingyi Xie
Zixuan Xing
Yajing Bo
Chenyu Chang
Fan Zhang
Fanpu Ji
Mu Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: COVID-19
Ovarian Cancer
Ovarian Cancer
Cervical Cancer
Cervical Cancer
Published in: Infectious Agents and Cancer / Issue 1/2024
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/s13027-024-00567-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

The prognostic role of PD-L1 expression and the presence of polyomavirus in Merkel cell carcinoma cases

Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis

Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi

Expression of 10 circulating cytokines/chemokines in HBV-related liver disease

Nelfinavir inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly

Keynote webinar | Spotlight on antibody–drug conjugates in cancer